辰欣藥業(603367.SH):奧沙利鉑甘露醇注射液和利巴韋林注射液納入國家醫保目錄
格隆匯 12 月 30日丨辰欣藥業(603367.SH)公佈,2020年12月28日,國家醫保局、人力資源和社會保障部發布關於印發《國家基本醫療保險、工傷保險和生育保險藥品目錄(2020年)》的通知(醫保發〔2020〕53號)。公司藥品奧沙利鉑甘露醇注射液和利巴韋林注射液共計兩個品種調入。
奧沙利鉑甘露醇注射液,2019年銷售收入6319.28萬元,佔公司2019年總營業收入的1.54%(經審計),2020年前三季度銷售收入4146.27萬元,佔公司1-9月營業收入的1.56%(未經審計)。
利巴韋林注射液,2019年銷售收入4571.08萬元,佔公司2019年總營業收入的1.11%(經審計),2020年前三季度銷售收入2049.49萬元,佔公司1-9月營業收入的0.77%(未經審計)。
《2020年國家醫保目錄》自2021年3月1日起正式執行,公司上述納入《2020年國家醫保目錄》的兩個產品,將有利於公司產品的市場銷售,未來對公司經營業績的影響暫無法估計。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.